Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION537 in advanced solid tumors
NCT04659096Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ION537 in solid tumor, sponsored by Ionis Pharmaceuticals. Primary endpoints: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Treatment-emergent Serious Adverse Event (TESAE) at 24 weeks, Number of Participants With Dose-limiting Toxicities at 24 weeks and 6 more. Started Jan 2021; status: completed.
02
Drugs
ION537
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04659096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659096.